反应 #619179

ord-c8525d917ec2437f8112b3e7b3760538

反应方程式

CC1CCC(N(C(=O)Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)s2)C2CCNCC2)CC1.Cl
4-{2-[3-(4-methyl-cyclohexyl)-3-piperidin-4-yl-ureido]-thiazol-5-ylmethyl}-piperazine-1-sulfonic acid dimethylamide hydrochloride
O=C(Cl)c1ccc(F)cc1
4-fluorobenzoyl chloride
→
CC1CCC(N(C(=O)Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)s2)C2CCN(C(=O)c3ccc(F)cc3)CC2)CC1
desired product
收率 73.0%
CC1CCC(N(C(=O)Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)s2)C2CCN(C(=O)c3ccc(F)cc3)CC2)CC1
4-{2-[3-[1-(4-Fluoro-benzoyl)-piperidin-4-yl]-3-(4-methyl-cyclohexyl)-ureido]-thiazol-5-ylmethyl}-piperazine-1-sulfonic acid dimethylamide
收率 73.0%

反应物

CC1CCC(N(C(=O)Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)s2)C2CCNCC2)CC1.Cl
4-{2-[3-(4-methyl-cyclohexyl)-3-piperidin-4-yl-ureido]-thiazol-5-ylmethyl}-piperazine-1-sulfonic acid dimethylamide hydrochloride
—
TEA
O=C(Cl)c1ccc(F)cc1
4-fluorobenzoyl chloride

试剂

无

反应条件

详细条件
See reaction.notes.procedure_details.

后处理

  1. 1
    其他Prepared

实验过程

Prepared as described in general procedure (N) using 4-{2-[3-(4-methyl-cyclohexyl)-3-piperidin-4-yl-ureido]-thiazol-5-ylmethyl}-piperazine-1-sulfonic acid dimethylamide hydrochloride (47 mg, 0.083 mmol), TEA (26 μL, 0.19 mmol) and 4-fluorobenzoyl chloride (10 μL, 0.083 mmol) to afford 39 mg (73%) of the desired product after purification.

来源

DOI: 10.6084/m9.figshare.5104873.v1专利: USRE045183E1uspto-grants-2014_10